Muhammad S Beg1,2, Arjun Gupta3, David Sher2,4, Sadia Ali5, Saad Khan1,2, Ang Gao6, Tyler Stewart3, Chul Ahn2,6, Jarett Berry7, Eric M Mortensen3,6,8. 1. Divisions of Hematology/Oncology. 2. Harold C. Simmons Cancer Center. 3. Departments of Internal Medicine. 4. Radiation Oncology. 5. Endocrinology and Metabolism. 6. Clinical Sciences, University of Texas-Southwestern Medical Center. 7. Cardiology. 8. VA North Texas Health Care System, Dallas, TX.
Abstract
OBJECTIVES: Preclinical studies have suggested that non-antineoplastic medication use may impact pancreatic cancer biology. We examined the association of several medication classes on pancreatic cancer survival in a large medical claims database. MATERIALS AND METHODS: Histologically confirmed pancreatic adenocarcinoma diagnosed between 2006 and 2009 were analyzed from the Surveillance, Epidemiology, and End Results-Medicare database with available part D data. Drug use was defined as having 2 prescriptions filled within 12 months of pancreatic cancer diagnosis. The following medication classes/combinations were analyzed: β-blocker, statin, insulin, metformin, thiazolidinedione, warfarin, heparin, β-blocker/statin, metformin/statin, and β-blocker/metformin. Multivariable Cox proportional hazard models adjusting for age, sex, race, stage at diagnosis, site of cancer, and Charlson comorbidity index were constructed to test the association between medication classes and overall survival. RESULTS: A total of 13,702 patients were included in the study; median age 76 years, 42.5% males, 77.1% white. The most common anatomic site and stage at diagnosis were head of the pancreas (49.9%) and stage 4 (49.6%), respectively. Ninety-four percent of patients died in the follow-up period (median overall survival 5.3 mo). Multivariable Cox regression analysis showed that use of β-blockers, heparin, insulin, and warfarin were significantly associated with improved survival (P<0.05 for each one), whereas metformin, thiazolidinedione, statin, and combination therapies were not. CONCLUSIONS: In this study, use of β-blockers, heparin, insulin, and warfarin were associated with improved survival in patients with pancreatic cancer. Additional studies are needed to validate these findings in the clinical setting.
OBJECTIVES: Preclinical studies have suggested that non-antineoplastic medication use may impact pancreatic cancer biology. We examined the association of several medication classes on pancreatic cancer survival in a large medical claims database. MATERIALS AND METHODS: Histologically confirmed pancreatic adenocarcinoma diagnosed between 2006 and 2009 were analyzed from the Surveillance, Epidemiology, and End Results-Medicare database with available part D data. Drug use was defined as having 2 prescriptions filled within 12 months of pancreatic cancer diagnosis. The following medication classes/combinations were analyzed: β-blocker, statin, insulin, metformin, thiazolidinedione, warfarin, heparin, β-blocker/statin, metformin/statin, and β-blocker/metformin. Multivariable Cox proportional hazard models adjusting for age, sex, race, stage at diagnosis, site of cancer, and Charlson comorbidity index were constructed to test the association between medication classes and overall survival. RESULTS: A total of 13,702 patients were included in the study; median age 76 years, 42.5% males, 77.1% white. The most common anatomic site and stage at diagnosis were head of the pancreas (49.9%) and stage 4 (49.6%), respectively. Ninety-four percent of patients died in the follow-up period (median overall survival 5.3 mo). Multivariable Cox regression analysis showed that use of β-blockers, heparin, insulin, and warfarin were significantly associated with improved survival (P<0.05 for each one), whereas metformin, thiazolidinedione, statin, and combination therapies were not. CONCLUSIONS: In this study, use of β-blockers, heparin, insulin, and warfarin were associated with improved survival in patients with pancreatic cancer. Additional studies are needed to validate these findings in the clinical setting.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Navid Sadeghi; James L Abbruzzese; Sai-Ching J Yeung; Manal Hassan; Donghui Li Journal: Clin Cancer Res Date: 2012-03-31 Impact factor: 12.531
Authors: Amanda Kirane; Kathleen F Ludwig; Noah Sorrelle; Gry Haaland; Tone Sandal; Renate Ranaweera; Jason E Toombs; Miao Wang; Sean P Dineen; David Micklem; Michael T Dellinger; James B Lorens; Rolf A Brekken Journal: Cancer Res Date: 2015-07-23 Impact factor: 12.701
Authors: Stefan von Delius; Muhammed Ayvaz; Stefan Wagenpfeil; Florian Eckel; Roland M Schmid; Christian Lersch Journal: Thromb Haemost Date: 2007-08 Impact factor: 5.249
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Matthew B Lipner; Raoud Marayati; Yangmei Deng; Xianxi Wang; Laura Raftery; Bert H O'Neil; Jen Jen Yeh Journal: PLoS One Date: 2016-01-13 Impact factor: 3.240
Authors: Garth W Tormoen; Tiffany C Blair; Shelly Bambina; Gwen Kramer; Jason Baird; Ramtin Rahmani; John M Holland; Owen J T McCarty; Michael J Baine; Vivek Verma; Nima Nabavizadeh; Michael J Gough; Marka Crittenden Journal: Int J Radiat Oncol Biol Phys Date: 2020-04-18 Impact factor: 7.038
Authors: Bernhard W Renz; Ryota Takahashi; Takayuki Tanaka; Marina Macchini; Yoku Hayakawa; Zahra Dantes; H Carlo Maurer; Xiaowei Chen; Zhengyu Jiang; C Benedikt Westphalen; Matthias Ilmer; Giovanni Valenti; Sarajo K Mohanta; Andreas J R Habenicht; Moritz Middelhoff; Timothy Chu; Karan Nagar; Yagnesh Tailor; Riccardo Casadei; Mariacristina Di Marco; Axel Kleespies; Richard A Friedman; Helen Remotti; Maximilian Reichert; Daniel L Worthley; Jens Neumann; Jens Werner; Alina C Iuga; Kenneth P Olive; Timothy C Wang Journal: Cancer Cell Date: 2017-12-14 Impact factor: 31.743
Authors: Wenting Du; Natalie Z Phinney; Huocong Huang; Zhaoning Wang; Jill Westcott; Jason E Toombs; Yuqing Zhang; Muhammad S Beg; Thomas M Wilkie; James B Lorens; Rolf A Brekken Journal: Mol Cancer Res Date: 2021-04-02 Impact factor: 5.852
Authors: Ondřej Fiala; Pavel Ostašov; Aneta Rozsypalová; Milan Hora; Ondřej Šorejs; Jan Šustr; Barbora Bendová; Ivan Trávníček; Jan Filipovský; Jindřich Fínek; Tomáš Büchler Journal: Target Oncol Date: 2021-08-07 Impact factor: 4.493